Anavex Life Sciences (STU:12X1) Total Liabilities : €10.92 Mil (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Total Liabilities?

Anavex Life Sciences's Total Liabilities for the quarter that ended in Jun. 2024 was €10.92 Mil.

Anavex Life Sciences's quarterly Total Liabilities declined from Dec. 2023 (€11.46 Mil) to Mar. 2024 (€8.79 Mil) but then increased from Mar. 2024 (€8.79 Mil) to Jun. 2024 (€10.92 Mil).

Anavex Life Sciences's annual Total Liabilities increased from Sep. 2021 (€9.18 Mil) to Sep. 2022 (€10.32 Mil) and increased from Sep. 2022 (€10.32 Mil) to Sep. 2023 (€11.74 Mil).

Anavex Life Sciences Total Liabilities Historical Data

The historical data trend for Anavex Life Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Total Liabilities Chart

Anavex Life Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Liabilities

Get a 7-Day Free Trial

4.58

6.20

9.18

10.32

11.74

Anavex Life Sciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Liabilities	Get a 7-Day Free Trial															10.20	11.74	11.46	8.79	10.92

Anavex Life Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Anavex Life Sciences's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.744	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	11.74

Total Liabilities	=	Total Assets (A: Sep. 2023 )	-	Total Equity (A: Sep. 2023 )
	=	144.66	-	132.915
	=	11.75

Anavex Life Sciences's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	10.919	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	10.92

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	131.486	-	120.567
	=	10.92

Anavex Life Sciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AVXL:USA 0HFR:UK 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences Headlines

No Headlines